Physician profile
John Baber
NPI 1588861710
$5,290.17
in general payments reported to CMS, 2019-2025
24 companies · $1,138 in 2025
The $1,138 reported for 2025 was more than what 75% of Pain Medicine (Physical Medicine & Rehabilitation) providers received nationally (typical 2025 total: $400).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $570 · 2020: $142 · 2021: $853 · 2022: $1,102 · 2023: $704 · 2024: $780 · 2025: $1,138.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,622.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,622.02 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $1,685.90 | 2019-2025 | Proclaim, Diamondback Peripheral, Esprit |
| Medtronic, INC. | $1,027.07 | 2021-2025 | Intellis Adaptivestim, Inceptiv |
| Boston Scientific Corporation | $883.88 | 2020-2025 | Wavewriter Alpha Prime 16 |
| Si-Bone, INC. | $335.64 | 2019-2025 | |
| Spr Therapeutics, INC | $267.11 | 2024-2025 | Sprint Pns System |
| Vertos Medical, INC. | $165.39 | 2022 | |
| Relievant Medsystems, INC. | $155.20 | 2023 | Intracept |
| Janssen Biotech, INC. | $126.95 | 2025 | Tremfya, Simponi Aria |
| Pfizer INC. | $106.92 | 2020-2024 | |
| Astrazeneca Pharmaceuticals LP | $102.86 | 2023 | Farxiga |
| Collegium Pharmaceutical, INC. | $93.30 | 2019-2025 | Belbuca, Nucynta |
| Lundbeck LLC | $60.35 | 2024-2025 | Vyepti |
| Averitas Pharma INC. | $54.46 | 2025 | Qutenza |
| Stryker Corporation | $36.22 | 2021 | |
| Painteq LLC | $27.98 | 2024 | Painteq |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Appliedvr INC | $25.74 | 2024 | Relievrx |
| Foundation Fusion Solutions, LLC | $25.05 | 2021-2025 | |
| Avanos Medical | $23.72 | 2019 | |
| Nalu Medical, INC. | $19.84 | 2025 | Nalu Neurostimulation System |
| Abbvie INC. | $19.06 | 2024 | |
| Trice Medical, INC. | $17.38 | 2024 | |
| Vertex Pharmaceuticals Incorporated | $15.61 | 2025 | |
| Ucb, INC. | $14.54 | 2022 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Baber listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.